Cellebrite DI (CLBT) EBIT (2020 - 2025)

Cellebrite DI's EBIT history runs 6 years deep, the most recent figure standing at $20.8 million for Q4 2025.

• On a quarterly basis, EBIT rose 32.29% year-over-year to $20.8 million in Q4 2025; TTM through Dec 2025 was $66.5 million, a 16.82% increase from a year earlier, with the FY2025 full-year figure at $66.5 million, up 16.82% from the prior year.
• EBIT advanced to $20.8 million in Q4 2025 per CLBT's latest filing, from $19.0 million in the prior quarter.
• Across five years, EBIT topped out at $20.8 million in Q4 2025 and bottomed at -$7.6 million in Q4 2022.
• The 5-year median for EBIT is $8.7 million (2021), against an average of $7.7 million.
• Across the five-year window, EBIT slumped 276.17% in 2022 and surged 6699.26% in 2024, its largest moves.
• Year by year, EBIT stood at $4.3 million in 2021, then slumped by 276.17% to -$7.6 million in 2022, then soared by 297.72% to $15.0 million in 2023, then climbed by 4.85% to $15.7 million in 2024, then surged by 32.29% to $20.8 million in 2025.
• Per Business Quant, the three latest CLBT EBIT figures stand at $20.8 million (Q4 2025), $19.0 million (Q3 2025), and $14.4 million (Q2 2025).